A pilot clinical study of Δ-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme
British Journal of Cancer, ISSN: 0007-0920, Vol: 95, Issue: 2, Page: 197-203
2006
- 302Citations
- 381Captures
- 22Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations302
- Citation Indexes293
- 293
- CrossRef221
- Policy Citations8
- Policy Citation8
- Patent Family Citations1
- Patent Families1
- Captures381
- Readers381
- 381
- Mentions22
- News Mentions11
- News11
- Blog Mentions9
- Blog9
- References2
- Wikipedia2
Most Recent News
No good evidence that ‘banned’ substances reliably destroy cancer cells in humans
What was claimed Cannabis oil destroys cancer cells but it has been banned by the US Food and Drug Administration (FDA). Our verdict There is
Article Description
Δ-Tetrahydrocannabinol (THC) and other cannabinoids inhibit tumour growth and angiogenesis in animal models, so their potential application as antitumoral drugs has been suggested. However, the antitumoral effect of cannabinoids has never been tested in humans. Here we report the first clinical study aimed at assessing cannabinoid antitumoral action, specifically a pilot phase I trial in which nine patients with recurrent glioblastoma multiforme were administered THC intratumoraly. The patients had previously failed standard therapy (surgery and radiotherapy) and had clear evidence of tumour progression. The primary end point of the study was to determine the safety of intracranial THC administration. We also evaluated THC action on the length of survival and various tumour-cell parameters. A dose escalation regimen for THC administration was assessed. Cannabinoid delivery was safe and could be achieved without overt psychoactive effects. Median survival of the cohort from the beginning of cannabinoid administration was 24 weeks (95% confidence interval: 15-33). Δ-Tetrahydrocannabinol inhibited tumour-cell proliferation in vitro and decreased tumour-cell Ki67 immunostaining when administered to two patients. The fair safety profile of THC, together with its possible antiproliferative action on tumour cells reported here and in other studies, may set the basis for future trials aimed at evaluating the potential antitumoral activity of cannabinoids. © 2006 Cancer Research.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33745929641&origin=inward; http://dx.doi.org/10.1038/sj.bjc.6603236; http://www.ncbi.nlm.nih.gov/pubmed/16804518; https://www.nature.com/articles/6603236; https://dx.doi.org/10.1038/sj.bjc.6603236; http://www.nature.com/bjc/journal/v95/n2/full/6603236a.html; http://www.nature.com/doifinder/10.1038/sj.bjc.6603236
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know